RSS

Kymriah (tisagenlecleucel)

NHS England has announced a landmark deal, giving children and young people access to Novartis’ Kymriah (a chimeric antigen receptor T-cell, CAR-T, therapy) — a personalised therapy for the treatment of cancer. more

News

Swiss-based healthcare company, Novartis, has revealed that the US Food and Drug Administration (FDA) has approved its CAR-T therapy, Kymriah, for its second distinct indication. more

News

Novartis has received approval for its chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, from the US Food and Drug Administration (FDA). more

News